Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
13.49B
Enterprise Value
16.54B
Income
633.63M
Sales
6.29B
Book/sh
12.26
Cash/sh
1.81
Employees
18362
IPO
Nov 16, 1999
P/E
21.98
Forward P/E
13.55
PEG
1.45
P/S
2.15
P/B
2.63
P/C
17.79
P/FCF
15.88
EV/EBITDA
9.90
EV/Sales
2.63
Quick Ratio
1.11
Current Ratio
2.14
Debt/Eq
0.73
LT Debt/Eq
0.62
Option/Short
Yes / Yes
EPS (ttm)
1.47
EPS next Y
2.38
EPS next Q
0.66
EPS this Y
6.93%
EPS next Y
9.08%
EPS next 5Y
9.36%
EPS past 3/5Y
41.40% 6.97%
Sales past 3/5Y
5.84% 6.10%
EPS Y/Y TTM
31.02%
Sales Y/Y TTM
5.26%
EPS Q/Q
4.72%
Sales Q/Q
3.61%
Insider Own
0.06%
Insider Trans
0.00%
Inst Own
13.43%
Inst Trans
-6.41%
ROA
5.82%
ROE
11.80%
ROIC
7.51%
Gross Margin
68.21%
Oper. Margin
17.05%
Profit Margin
10.08%
SMA20
9.59%
SMA50
13.48%
SMA200
3.85%
Trades
Shs Outstand
424.66M
Shs Float
418.28M
52W High
37.09 -13.09%
52W Low
26.12 23.41%
Volatility
1.49% 1.58%
ATR (14)
0.67
RSI (14)
73.59
Beta
0.54
Rel Volume
2.45
Avg Volume
1.47M
Volume
1,739,149
Perf Week
7.02%
Perf Month
19.97%
Perf Quarter
8.57%
Perf Half Y
6.53%
Perf YTD
-1.75%
Perf Year
-12.92%
Perf 3Y
33.87%
Perf 5Y
-9.81%
Perf 10Y
13.38%
Prev Close
30.17
Price
32.24
Change %
6.85%
Consensus
Hold
Avg. Price Target
$31.81
Implied Upside
-1.3%
Analysts13incl. previous ratings
Rating Distribution0 Buy · 12 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 08, 2026Downgrade
BAC logoBBofA Securities
Buy → Neutral
Sep 02, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight
Aug 31, 2026Initiated
BBTIG Research
Neutral
Aug 06, 2026Downgrade
JPM logoJJP Morgan
Overweight → Neutral
Aug 05, 2026Downgrade
BCS logoBBarclays
Equal Weight → Underweight
Jun 04, 2026Downgrade
KKepler
Buy → Hold
Dec 15, 2025Downgrade
RY logoRRBC Capital Mkts
Outperform → Sector Perform
Oct 14, 2025Downgrade
BBernstein
Outperform → Mkt Perform$37.50+16.3%
Apr 25, 2025Downgrade
HSBC logoHHSBC Securities
Buy → Hold
Mar 12, 2025Downgrade
UBS logoUUBS
Buy → Neutral
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
CEO & DirectorDr. Deepak S. Nath Ph.D.
Interim CFOMr. Pierre Palassian
President of Global OperationsMr. Paul Connolly
Head of Investor RelationsEmily Heaven
Group General Counsel & Company SecretaryMs. Helen Barraclough